Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/31985
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | BATISTA, Rafael L. | |
dc.contributor.author | MUSOLINO, Nina R. C. | |
dc.contributor.author | CESCATO, Valter A. S. | |
dc.contributor.author | SILVA, Gilberto O. da | |
dc.contributor.author | MEDEIROS, Raphael S. S. | |
dc.contributor.author | HERKENHOFF, Clarissa G. B. | |
dc.contributor.author | TRARBACH, Ericka B. | |
dc.contributor.author | CUNHA-NETO, Malebranche B. | |
dc.date.accessioned | 2019-05-30T13:48:02Z | |
dc.date.available | 2019-05-30T13:48:02Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, v.42, n.2, p.221-227, 2019 | |
dc.identifier.issn | 0277-3732 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/31985 | |
dc.description.abstract | Background: Complete tumor removal by transsphenoidal surgery is usually difficult for large nonfunctioning pituitary adenomas (NFPAs). A validated medical treatment may be useful for their management. This study evaluates the clinical efficacy of the dopaminergic agonist cabergoline for residual NFPA. Design, Setting, and Participants: We conducted a randomized, parallel, open-label clinical trial that compared cabergoline with nonintervention in patients with residual NFPA after transsphenoidal surgery over 2 years. The primary outcome was clinical efficacy (tumor reduction). The secondary outcome was the relationship between tumor dopamine D2 receptor (D2R) expression and clinical responsiveness. Tumor measurements and clinical evaluations were performed every 6 months. Results: In total, 59 and 57 individuals were randomly assigned to the study and control groups, respectively. At the end of the study, residual tumor shrinkage, stabilization, and enlargement were observed in 28.8%, 66.1%, and 5.1% of patients, respectively, in the medical-therapy group and in 10.5%, 73.7%, and 15.8% of patients, respectively, in the control group (P=0.01). The progression-free survival rate was 23.2 and 20.8 months for the study and control groups, respectively (P=0.01). D2R was not associated with cabergoline responsiveness. No major side effects were related to cabergoline use. Conclusions: Cabergoline was an effective drug for treating residual NFPA, and its use was associated with a high rate of tumor shrinkage ( NCT03271918). | eng |
dc.description.sponsorship | Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESP [2014/16327-1] | |
dc.language.iso | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | eng |
dc.relation.ispartof | American Journal of Clinical Oncology-Cancer Clinical Trials | |
dc.rights | restrictedAccess | eng |
dc.subject | nonfunctioning adenoma | eng |
dc.subject | cabergoline | eng |
dc.subject | D2R expression | eng |
dc.subject.other | receptor expression | eng |
dc.subject.other | medical therapy | eng |
dc.subject.other | dopamine 2 | eng |
dc.subject.other | radiotherapy | eng |
dc.subject.other | diagnosis | eng |
dc.subject.other | mortality | eng |
dc.subject.other | disease | eng |
dc.title | Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial | eng |
dc.type | article | eng |
dc.rights.holder | Copyright LIPPINCOTT WILLIAMS & WILKINS | eng |
dc.identifier.doi | 10.1097/COC.0000000000000505 | |
dc.identifier.pmid | 30540568 | |
dc.subject.wos | Oncology | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.description.beginpage | 221 | |
hcfmusp.description.endpage | 227 | |
hcfmusp.description.issue | 2 | |
hcfmusp.description.volume | 42 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000465420000019 | |
hcfmusp.origem.id | 2-s2.0-85060373250 | |
hcfmusp.publisher.city | PHILADELPHIA | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Ayuk J, 2009, PITUITARY, V12, P35, DOI 10.1007/s11102-007-0083-1 | eng |
hcfmusp.relation.reference | Borba CG, 2015, CASE REP ONCOL MED, DOI 10.1155/2015/810367 | eng |
hcfmusp.relation.reference | Bulwer C, 2017, CLIN ENDOCRINOL, V86, P862, DOI 10.1111/cen.13339 | eng |
hcfmusp.relation.reference | Castinetti F, 2015, ANN ENDOCRINOL-PARIS, V76, P220, DOI 10.1016/j.ando.2015.04.007 | eng |
hcfmusp.relation.reference | Chanson P, 2015, ANN ENDOCRINOL-PARIS, V76, P239, DOI 10.1016/j.ando.2015.04.002 | eng |
hcfmusp.relation.reference | Colao A, 2008, ENDOCR-RELAT CANCER, V15, P905, DOI 10.1677/ERC-08-0181 | eng |
hcfmusp.relation.reference | Delpont B, 2017, MOVEMENT DISORD, V32, P1566, DOI 10.1002/mds.27101 | eng |
hcfmusp.relation.reference | DICHIRO G, 1962, AMER J ROENTGENOL RA, V87, P989 | eng |
hcfmusp.relation.reference | Gabalec F, 2015, PHYSIOL RES, V64, P369 | eng |
hcfmusp.relation.reference | Gabalec F, 2012, PITUITARY, V15, P222, DOI 10.1007/s11102-011-0316-1 | eng |
hcfmusp.relation.reference | Gagliano T, 2013, PITUITARY, V16, P91, DOI 10.1007/s11102-012-0380-1 | eng |
hcfmusp.relation.reference | Garcia EC, 2013, PITUITARY, V16, P189, DOI 10.1007/s11102-012-0403-y | eng |
hcfmusp.relation.reference | Greenman Y, 2016, EUR J ENDOCRINOL, V175, P63, DOI 10.1530/EJE-16-0206 | eng |
hcfmusp.relation.reference | Greenman Y, 2017, EUR J ENDOCRINOL, V177, pR113, DOI 10.1530/EJE-17-0216 | eng |
hcfmusp.relation.reference | Greenman Y, 2015, ENDOCRINE, V50, P51, DOI 10.1007/s12020-015-0685-8 | eng |
hcfmusp.relation.reference | Halperin I, 2012, CLIN ENDOCRINOL, V77, P275, DOI 10.1111/j.1365-2265.2012.04349.x | eng |
hcfmusp.relation.reference | Ioachimescu AG, 2012, NEUROSURGERY, V71, P296, DOI 10.1227/NEU.0b013e318257c1f0 | eng |
hcfmusp.relation.reference | Kim MY, 2016, RADIAT ONCOL J, V34, P121, DOI 10.3857/roj.2016.01683 | eng |
hcfmusp.relation.reference | LUNDIN P, 1992, J COMPUT ASSIST TOMO, V16, P519, DOI 10.1097/00004728-199207000-00004 | eng |
hcfmusp.relation.reference | Mano T, 2017, CLIN NEUROPHARMACOL, V40, P219, DOI 10.1097/WNF.0000000000000243 | eng |
hcfmusp.relation.reference | Mercado M, 2017, ENDOCRINOL DIAB NUTR, V64, P384, DOI 10.1016/j.endinu.2017.05.009 | eng |
hcfmusp.relation.reference | Minniti G, 2016, REP PRACT ONCOL RADI, V21, P370, DOI 10.1016/j.rpor.2014.09.004 | eng |
hcfmusp.relation.reference | Molitch ME, 2017, JAMA-J AM MED ASSOC, V317, P516, DOI 10.1001/jama.2016.19699 | eng |
hcfmusp.relation.reference | Neto LV, 2015, CLIN ENDOCRINOL, V82, P739, DOI 10.1111/cen.12684 | eng |
hcfmusp.relation.reference | Nishioka H, 2015, ENDOCR PATHOL, V26, P349, DOI 10.1007/s12022-015-9398-z | eng |
hcfmusp.relation.reference | Olsson DS, 2015, J CLIN ENDOCR METAB, V100, P2651, DOI 10.1210/jc.2015-1475 | eng |
hcfmusp.relation.reference | Perez-Esparza R, 2017, J NEUROPSYCH CLIN N, V29, P295, DOI 10.1176/appi.neuropsych.16110313 | eng |
hcfmusp.relation.reference | Pivonello R, 2004, J CLIN ENDOCR METAB, V89, P1674, DOI 10.1210/jc.2003-030859 | eng |
hcfmusp.relation.reference | Rogers A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5390 | eng |
hcfmusp.relation.reference | Sebastian P, 2016, REP PRACT ONCOL RADI, V21, P466, DOI 10.1016/j.rpor.2016.06.002 | eng |
hcfmusp.relation.reference | Serra C, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15564 | eng |
hcfmusp.relation.reference | Voon V, 2009, LANCET NEUROL, V8, P1140, DOI 10.1016/S1474-4422(09)70287-X | eng |
hcfmusp.relation.reference | Vroonen L, 2017, ENDOCRINE, V55, P248, DOI 10.1007/s12020-016-1120-5 | eng |
hcfmusp.relation.reference | Wang SS, 2016, ARCH MED SCI, V12, P576, DOI 10.5114/aoms.2016.59932 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1537-453X | |
hcfmusp.citation.scopus | 42 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/IPq Artigos e Materiais de Revistas Científicas - LIM/25 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_BATISTA_Cabergoline_in_the_Management_of_Residual_Nonfunctioning_Pituitary_2019.PDF Restricted Access | publishedVersion (English) | 233.95 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.